Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14540MR)

This product GTTS-WQ14540MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14540MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9347MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ8474MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2536MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ8146MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ788MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ5274MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ10332MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ10058MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW